Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,582 shares of the biopharmaceutical company’s stock after selling 152 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,004,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Finally, Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $545.94 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business’s fifty day moving average price is $537.90 and its two-hundred day moving average price is $597.62. The firm has a market capitalization of $57.86 billion, a PE ratio of 13.76, a P/E/G ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the company earned $11.56 earnings per share. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on REGN. The Goldman Sachs Group decreased their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Morgan Stanley reissued an “overweight” rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price objective for the company. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research report on Friday, April 25th. Finally, Citigroup reissued a “buy” rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $835.74.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.